MAPT and Alzheimer disease: Immunohistochemical studies of human postmortem tissues and immunoreactivity with AD brain extracts with PAD-specific commercial mAb (TNT-1) demonstrated that the exposure of the N-terminal region of Tau is an early event in AD that is becoming progressively more prominent in the later stages of AD62,66–68.